BioSig Technologies, Inc. is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. The Company’s product, the PURE EP Platform, a non-invasive class II device, provides real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures. Integrating with existing systems in the EP lab, PURE EP is designed to pinpoint even the complex signals to maximize procedural success and efficiency. The PURE EP System is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise from other equipment, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP is a signal processing platform that combines advanced hardware and software to address known challenges associated to signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time.
企業コードBSGM
会社名BioSig Technologies Inc
上場日Sep 22, 2014
最高経営責任者「CEO」Mr. Henry Mcphie
従業員数5
証券種類Ordinary Share
決算期末Sep 22
本社所在地55 Greens Farms Road
都市WESTPORT
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号06880
電話番号12034095444
ウェブサイトhttps://www.biosig.com/
企業コードBSGM
上場日Sep 22, 2014
最高経営責任者「CEO」Mr. Henry Mcphie
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし